Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - methyldopa sesquihydrate, quantity: 283 mg (equivalent: methyldopa, qty 250 mg) - tablet, film coated - excipient ingredients: ethylcellulose; disodium edetate; magnesium stearate; guar gum; sodium starch glycollate; colloidal anhydrous silica; citric acid; titanium dioxide; hypromellose; sunset yellow fcf; quinoline yellow; macrogol 400 - indications as at 7 may 1996: hypertension (mild, moderate to severe)

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium hydrogen carbonate; calcium carbonate - chewable tablet - 250 mg/133.5 mg/80 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - calcium carbonate; magnesium carbonate; simeticone - chewable tablet - 680 mg/80 mg/25 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations; silicones

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - calcium carbonate; magnesium carbonate - chewable tablet - 680 mg/80 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - calcium carbonate; magnesium carbonate - chewable tablet - 680 mg/80 milligram(s) - magnesium carbonate; calcium carbonate; antacids, other combinations

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 300.715 mg - tablet, film coated - excipient ingredients: crospovidone; calcium carbonate; microcrystalline cellulose; calcium stearate; croscarmellose sodium; purified water; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - cefuroxime axetil, quantity: 300.715 mg - tablet, film coated - excipient ingredients: crospovidone; croscarmellose sodium; calcium carbonate; calcium stearate; purified water; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; titanium dioxide; hypromellose; propylene glycol; brilliant blue fcf aluminium lake - cefuroxime is indicated for the treatment of the following mild to moderately severe infections in adults caused by sensitive bacteria: acute upper respiratory infections: otitis media, sinusitis, tonsillitis and pharyngitis. acute exacerbations of chronic bronchitis, or acute bronchitis. skin and skin structure infections for example, furunculosis, pyoderma and impetigo. acute uncomplicated gonococcal urethritis, and cervicitis due to non-penicillinase producing gonococci.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - ciprofloxacin hydrochloride - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ciprofloxacin hydrochloride - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - ciprofloxacin hydrochloride - oral tablet - 250mg